Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover study of glycopyrronium versus tiotropium for early bronchodilation in moderate to severe COPD
2013-001445-13Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of glycopyrronium and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: FEV1 AUC0-2h. Started May 2013; status: completed.
02
Drugs
glycopyrroniumtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-001445-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001445-13.